---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-000730"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T07:36:25.302283+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Immunic announces public offering of warrants and posts extended phase 2 CALLIPER data

## Summary
- Commenced underwritten public offering of pre-funded warrants and Series A (expire Dec 31, 2025) and Series B (5-year) warrants.
- Leerink Partners sole bookrunner; proceeds to fund clinical trials and general corporate purposes.
- Posted updated corporate presentation with extended data from phase 2 CALLIPER trial of vidofludimus calcium in progressive MS.
- Offering is subject to market conditions; no assurance of completion or final terms.

## SEC filing metadata
- accession: 0001193805-25-000730
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380525000730/0001193805-25-000730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380525000730/e664552_8k-immuniclaunch.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-000730
- JSON: https://secwatch.observer/filing/0001193805-25-000730.json
- Plain text: https://secwatch.observer/filing/0001193805-25-000730.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.